Predictive criteria for prostate cancer detection in men with serum PSA concentration of 2.0 to 4.0 ng/mL

Urology

Volumn 66, Issue 3, 2005, Pages 542-546

  Kravchick, Sergey ^a   Peled, Ronit ^b   Dorfman, Dov ^b   Agulansky, Leonid ^b   Ben Dor, David ^b   Cytron, Shmuel ^b  

^a BARZILAI MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; STATISTICAL SIGNIFICANCE; TRANSRECTAL ULTRASONOGRAPHY;

AGED; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 24144452520     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2005.04.012     Document Type: Article

References (20)

1. J.W. Colberg, D.S. Smith, W.J. Catalona Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0 ng/ml J Urol 149 1993 507 509
2. D.S. Smith, W.J. Catalona, J.D. Herschman Longitudinal screening for prostate cancer with prostate-specific antigen JAMA 276 1996 1309 1315
3. F.H. Schröder, I. van der Cruijsen-Koeter, H.J. de Koning Prostate cancer detection at low prostate specific antigen J Urol 163 2000 806 812
4. F. Recker, M. Kwiatkowski, A. Huber Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng/ml: combined with free-to-total ratio 20% or less: the Aarau experience J Urol 166 2001 851 884
5. C.H. Harris, B.L. Dalkin, E. Martin Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng/ml or less J Urol 157 1997 1740 1743
6. W.J. Catalona, D.S. Smith, D.K. Ornstein Prostate cancer detection in men with PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free measurements JAMA 277 1997 1452 1455
7. D.S. Smith, G.F. Carvalhal, D.E. Mager Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men J Urol 160 1998 1734 1738
8. K.A. Roehl, J.A.V. Antenor, W.J. Catalona Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6-4.0 ng/ml range J Urol 168 2002 922 925
9. M.A. Hoffman, W.C. DeWolf, A. Morgentaler Is low serum free testosterone a marker for high grade prostate cancer? J Urol 163 2000 824 827
10. A. Morgentaler, C.O. Bruning III, W.C. DeWolf Occult prostate cancer in men with low serum testosterone levels JAMA 276 1996 1904 1906
11. G. Schatzl, S. Madersbacher, T. Thurridl High-grade prostate cancer is associated with lower serum testosterone levels Prostate 47 2001 52 58
12. J.I. Epstein, D.W. Chan, L.J. Sokoll Nonpalpable stage T1c prostate cancer prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings J Urol 160 1998 2407 2411
13. J.S. Krumholtz, G.F. Carvalhal, C.G. Ramos Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features Urology 60 2002 469 473
14. R.S. Punglia, A.V. D'Amico, W.J. Catalona Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen N Engl J Med 349 2003 335 342
15. T.A. Stamey, I.M. Johnstone, J.E. McNeal Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology prostate specific antigen cure rates appear constant between 2 and 9 ng/ml J Urol 167 2002 103 111
16. G. Schatzl, C. Brossner, S. Schmid Prostate Study Group of the Austrian Society of Urology Endocrine status in elderly men with lower urinary tract symptoms correlation of age, hormonal status, and lower urinary tract function Urology 55 2000 397 402
17. A.V. D'Amico, M.-H. Chen, S.B. Malkowicz Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate cancer and a prostatic specific antigen level of 4 ng/ml or less J Urol 167 2002 2025 2031
18. R. Raaijmakers, B.G. Blijenberg, J.A. Finlay Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness J Urol 171 2004 2245 2249
19. M. Lujan, A. Paez, E. Miravalles Prostate cancer detection is also relevant in low prostate specific antigen ranges Eur Urol 45 2004 155 159
20. I.M. Thompson, D.K. Pauler, P.J. Goodman Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter N Engl J Med 350 2004 2239 2246